Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 110Other hematologic neoplasm 59Genitourinary 55Lymphoid 42Gastrointestinal 33Thoracic 28Breast 28Gynecologic 27CNS 21Other solid neoplasm 18Head & Neck 17Myeloid 12Sarcoma 10Plasma cell 8Tumor-Agnostic 6Classical hematology 2NET 1Endocrine 1

Conditions

Sarcoma 1Neuroendocrine Tumors 1Head and Neck Neoplasms 1

Interventions

Everolimus 61lutetium Lu 177 dotatate 53Magnetic Resonance Spectroscopy 39pembrolizumab 31Temozolomide 31Cisplatin 29Nivolumab 26Octreotide 25lanreotide 24gallium Ga 68 dotatate 24cabozantinib 22pasireotide 21lenvatinib 203-Iodobenzylguanidine 20Etoposide 19Sunitinib 18Specimen Handling 18Paclitaxel 18Carboplatin 18Capecitabine 18surufatinib 16Bevacizumab 16trametinib 15dabrafenib 15Sorafenib 14Doxorubicin 14Ipilimumab 13Thyrotropin Alfa 12Surgical Procedures, Operative 12Injections 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interleukin-2 × Endocrine × Clear all
NCT04166006 2024-09-19

RaC-Ad

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Recruiting
51 enrolled
EndocrineHead & NeckNETSarcoma

Head and Neck Neoplasms, Sarcoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡